Table 1. TRAIL-R1 and TRAIL-R2 cell surface expression on tumour cell lines.
| Cell line | Tumour type | TRAIL-R1 expression | TRAIL-R2 expression |
|---|---|---|---|
| SW480 | Colon adenocarcinoma | 3.4±1.3 | 5.9±2.0 |
| H2122 | Non-small-cell lung carcinoma | 3.1±0.2 | 7.1±0.3 |
| A498 | Renal cell carcinoma | 2.7±1.2 | 6.4±1.1 |
| ST486 | Burkitt's lymphoma | 1.9±0.1 | 0.6±0.2 |
| Colo205 | Colon adenocarcinoma | 1.8±0.6 | 7.4±2.1 |
| SU.86.86 | Pancreatic ductal carcinoma | 1.8±0.4 | 2.9±0.2 |
| H460 | Non-small-cell lung carcinoma | 1.7±0.5 | 4.0±1.0 |
| SNU-398 | Hepatocellular carcinoma | 1.6±0.2 | 3.2±0.0 |
| TTn | Oesophageal squamous carcinoma | 1.45±0.4 | 1.0±0.3 |
| HCT116 | Colon adenocarcinoma | 1.4±0.2 | 3.4±0.9 |
| JURL-MK1 | Chronic myeloid leukaemia | 1.15±0.1 | 2.6±0.5 |
| RL95-2 | Uterine endometrial carcinoma | 1.2±0.2 | 1.9±0.2 |
| ES2 | Ovarian clear cell carcinoma | 1.1±0.1 | 4.9±1.7 |
| WM793B | Melanoma | 1.0±0.09 | 10.2±0.5 |
TRAIL-R1 and TRAIL-R2 expression was determined by FACs analysis and is expressed as the fold-increase in mean fluorescent signal of commercial mouse TRAIL-R1 or R2 antibody vs isotype control antibody. The data is the average±s.d. from two or more experiments.